New health apps have been released by pharma/device companies and health professionals on daily basis, lately pharmaceutical giants have withdrawn nine apps from the iTunes store. The current withdrawn doesn’t reflect that the pharma industry has fallen out of love with Apple’s iphone, but it will continue to support other apps they have developed for the iPhone platform.
The major companies who withdrawn the apps are Pfizer, Johnson & Johnson and Merck.
Pfizer has pulled a few apps aimed at the Spanish market – Dos Au Mur, Les Meningo – Smash Pursuit and HemoTouch apps, three French iPhone apps for patients and their families that focused on ankylosing spondylitis, meningitis and haemophilia respectively.
Johnson & Johnson has pulled its Pneumonia Management Tool, an app that was developed by Ortho-McNeil-Janssen Pharmaceuticals to assist US healthcare professionals in their clinical decision-making. It also included current trends in national and local antibiotic resistance patterns.
Merck has withdrawn five apps from the iTunes– the Temodar Dosing Calculator, DAS28 Calculator for Healthcare Professionals, Remicade Dosage Calculator for Healthcare Professionals, Remicade RRP Matrix for...
Healthcare Professionals and Bridion Dose Calculator. Among all, the Remicade and Bridion apps were produced solely for the UK market.
There could be any number of reasons for pulling these apps — but non-approved DTC (direct to consumers) advertising might be on top of the list as it is not permitted in the United Kingdom.
Well! Pfizer, Merck and J&J still have a number of iPhone apps available, including ones for healthcare professionals as well as patients.